Journal of Clinical Oncology
Articles in this Issue
Serum albumin as an early predictor of survival in patients receiving antibody-drug conjugates.
e15041 Background: Decreased baseline and cycle 1 (C1) serum albumin (ALB) predicts shorter overall survival (OS) in pts w...
Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin, and 5-FU/levoleucovorin) as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Update from a single-arm, open-label phase I/II trial (SYLT-023).
4030 Background: Tisle is an anti-PD-1 antibody. The combination of Tisle + XELOX/FP is a first-line treatment of AGC in C...
Role of iron supplementation in the efficacy of immune checkpoint inhibitors (ICIs): A real-world propensity-matched analysis.
11131 Background: Iron plays a crucial role in the induction of ferroptosis mediated by immune checkpoint inhibitors (ICIs...
Long term outcomes of central neurocytoma in a multi-institutional cohort: The role of radiotherapy and Ki-67.
2089 Background: Central neurocytomas (CNs) are rare, WHO grade 2 brain tumors that can have relatively high recurrence ra...
Efficacy and hematopoietic recovery of high-dose melphalan with stem cell rescue as bridging to CAR-T compared with non-intensive bridging in relapsed/refractory multiple myeloma.
7544 Background: Bridging therapy is required for disease control in relapsed/refractory multiple myeloma (RRMM) patients...
Identifying barriers to prescribing PARP inhibitors, including olaparib, in advanced ovarian cancer.
e17560 Background: Despite improvements in survival with poly (ADP-ribose) polymerase inhibitors (PARPi) as first-line mai...
Gastric cancer outcomes in adolescents and young adults in Alberta, Canada.
e16032 Background: Gastric cancer (GC) poses a significant challenge in Canada, with survival rates at 29%. Adolescents an...
Determinants of recurrence after curative gastrectomy in young-onset gastric cancer: A Latin American cohort.
e16132 Background: Young-onset gastric cancer with curative surgery have limited data on prognostic factors. We evaluated...
Leader-member exchange (LMX) and workforce outcomes in radiation oncology: A preliminary generational comparison.
9038 Background: Job satisfaction and turnover intention remain crucial outcomes for healthcare organizations incurring su...
GRACE: A conversational AI platform for geriatric oncology risk and capability evaluation.
1658 Background: Comprehensive geriatric assessment (CGA) is a multidimensional evaluation of health in older adults and e...
Listening, explaining, caring: Patient experience in an oncology primary care clinic background.
e13790 Background: Cancer survivors experience a range of late effects and long-term comorbid conditions due to shared ris...
Spatial fractionated radiotherapy (SCART) remodeling of the tumor immune microenvironment and changes to ablative effects in murine models: Spatial transcriptomic and histopathologic evidence.
e15100 Background: Spatially fractionated radiotherapy (SFRT) delivers heterogeneous dose distributions to improve the the...
Circulating HPV DNA for early detection of minimal residual disease after definitive therapy in oropharyngeal cancer: A phase II biomarker-driven study.
6069 Background: Persistent detection of circulating HPV DNA (cfHPVDNA) in plasma following definitive therapy for HPV-pos...
Young-onset prostate cancer in the real world: A single-institution cohort of 126 patients diagnosed before age 55.
e17136 Background: Prostate cancer diagnosed before the age of 55 years is considered early-onset disease and represents a...
Management of chemotherapy-induced adverse events in patients with metastatic pancreatic ductal adenocarcinoma: A US-based modified Delphi consensus.
e16400 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is an aggressive malignancy with poor prognosis. Ch...
Trends and disparities in pancreatic carcinoma mortality among adults with type 2 diabetes mellitus in the United States: A CDC-based retrospective analysis (2000-2023).
e16418 Background: Type 2 Diabetes Mellitus is a potent risk factor for pancreatic cancer, which remains the leading cause...
Baseline corticosteroid use and outcomes in non–small cell lung cancer patients receiving immune checkpoint inhibitors, stratified by indication.
11184 Background: Baseline systemic corticosteroids are often prescribed to patients with non-small cell lung cancer (NSCL...
Trends in biosimilar bevacizumab adoption and Medicare spending by socioeconomic deprivation and rurality, 2019-2023.
1529 Background: Biosimilar bevacizumab has the potential to reduce oncology drug spending, but the equity of its real-wor...
Young breast cancer patients and molecular reclassification using RNA-sequencing.
e12591 Background: Choice of breast cancer (BC) treatment is to a large extent based on immunohistochemistry (IHC) subtypi...
MicroRNAs as surrogate biomarkers of future endometrial malignancy in women with endometrial hyperplasia without atypia and an open-label randomized trial of metformin, weight control, and exercise intervention.
5622 Background: Endometrial hyperplasia (EH) is regarded as an endometrial cancer (EC) precursor. The severity of atypia...
Long term follow-up results and prognosis analysis of TPF regimen chrono-chemotherapy combined with cisplatin concurrent chemoradiotherapy for the treatment of distant nasopharyngeal carcinoma.
e18034 Background: To research whether TPF (Docetaxel plus Fluorouracil plus Cisplatin) chrono-chemotherapy combined with...
Real-world analysis of the association between new-onset depression and outcomes in metastatic breast cancer.
1117 Background: Depression is prevalent in patients with advanced cancers and it may influence the disease course and tre...
Galeterone and gemcitabine in advanced pancreatic ductal adenocarcinoma.
e16433 Background: Advanced pancreatic cancer (PC) has limited chemotherapeutic options and a dismal prognosis. Mutant KRA...
Frailty phenotypes and acute care escalation in hospitalized patients with solid tumors: A National Inpatient Sample analysis, 2016–2023.
e23202 Background: Frailty-aware oncology is increasingly emphasized, yet inpatient frailty is inconsistently captured and...
Efficacy and safety of pralsetinib in advanced or metastatic <i>RET</i> -altered thyroid cancer (TC): Final analysis of the phase 1/2 ARROW study.
6028 Background: RET alterations are targetable oncogenic drivers in multiple solid tumors and TCs. Pr...